背景:抑郁症是2019年冠状病毒病后(COVID-19)患者的常见症状,可诊断为COVID-19后抑郁或COVID-19后综合征的调节障碍(AD)。最近,有报道称,用草药干预治疗COVID-19后综合征.然而,目前尚无综合治疗方法治疗COVID-19后综合征的AD研究。这是一例符合CARE要求的病例报告,该患者被诊断为COVID-19后综合征的AD,并通过综合个性化医学护理(IPMC)得到改善。
方法:一名84岁女性患者出现抑郁症状,失眠,心悸,COVID-19诊断后消化不良。
方法:根据《精神疾病诊断和统计手册》,患者被诊断为COVID-19导致的AD,第五版。
方法:患者采用IPMC方法治疗:常规西药用中药改善症状,针灸,和韩国传统医学的艾灸疗法,以改善她的一般状况。
结果:抑郁症,失眠,心悸,消化不良,在治疗前后通过各种问卷评估总体生活质量。在抑郁量表上得分明显下降,失眠的严重程度显著改善。治疗后,胃肠道症状消失了,和自主神经系统平衡改善。生活质量指标也显示出显着提高。
结论:本研究是首例证明使用IPMC后COVID-19症状改善的病例报告。值得注意的是,这项研究中的患者在使用IPMC方法治疗后逐渐减少了抗抑郁药。需要进一步的研究来建立更有资格的证据来证明IPMC治疗COVID-19综合征后AD的有效性和安全性。
BACKGROUND: Depression is a common symptom in post-coronavirus disease 2019 (COVID-19) patients, which can be diagnosed with post-COVID-19 depression or adjustment disorder (AD) of post-COVID-19 syndrome. Recently, there have been
reports of treating post-COVID-19 syndrome with herbal interventions. However, there are no studies of AD of post-COVID-19 syndrome treated with an integrative approach. This is a CARE-compliant
case report of a patient diagnosed with AD of post-COVID-19 syndrome and improved with integrative personalized medicine care (IPMC).
METHODS: An 84-year-old female patient presented symptoms of depression, insomnia, palpitations, and dyspepsia after COVID-19 diagnosis.
METHODS: The patient was diagnosed with AD due to COVID-19 according to Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition.
METHODS: The patient was treated with the IPMC approach: conventional Western drugs for symptom improvements with herbal medicine, acupuncture, and moxibustion therapies of traditional Korean medicine to enhance her general conditions.
RESULTS: Depression, insomnia, palpitations, dyspepsia, and overall quality of life were assessed through various questionnaires before and after treatment. Scores notably decreased across depression scales, and insomnia severity improved significantly. After treatment, gastrointestinal symptoms vanished, and autonomic nervous system balance improved. Quality of life metrics also showed remarkable enhancement.
CONCLUSIONS: This study is the first
case report to demonstrate improvement in AD of post-COVID-19 symptoms using IPMC. It is noteworthy that the patient in this study tapered off their antidepressant medication after the treatment with the IPMC approach. Further studies are needed to establish more qualified evidence to show the effectiveness and safety of IPMC for AD of post-COVID-19 syndrome.